
NCTN Thoracic Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



NCTN Thoracic Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

Sub-study: EAY191-E5 (KRAS G12C mutation)

EAY191
(ComboMATCH)

Sub-study: EAY191-N5 (HER2 amplified)

NCTN Thoracic Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive
A021901	H	Bronchial Neuroendocrine Tumors
A081801	Ш	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
		A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-
A082002	11/111	Negative, Advanced Non-Small Cell Lung Cancer
A082101	II	Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid Mesothelioma
		Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for
A092001	H	Peritoneal Mesothelioma
		Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Participants with Metastatic Non-Small-
CCTG-BR38	Ш	Cell Lung Cancer A Randomized Phase 3 Trial
CTIU2317-		Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer -
A082304-S2402	Ш	PROSPECT LUNG
EA5162	H	Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
		Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291
		(Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer
EA5182	Ш	(NSCLC)
		A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult
EA5221	Ш	with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
		A Randomized Phase III Trial of Checkpoint Blockade in Lung CancEr Patients in the Adjuvant Setting Based on
EA5231	Ш	Pathologic Response Following Neoadjuvant Therapy (CLEAR)
		A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small
LUNGMAP	Other	Cell Lung Cancer (Lung-MAP Screening Study)
NRG-LU007	11/111	RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
		Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by
NRG-LU008	Ш	Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
		A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for
		Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent
S1800E	11/111	Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
		A Randomized Phase III Trial of MRI Surveillance with or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell
S1827	Ш	Lung Cancer
		A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in
		Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-
S1900G	II	Study)
		A Phase II Study of Amivantamab SC (Subcutaneous) in Participants with MET Amplification-Positive Stage IV or
S1900J	II	Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
		A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping
S1900K	II	Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
		A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC
S1933	II	Patients with Borderline Performance Status
		PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance
S2409	II	Durvalumab with or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
		A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non
S2414	Ш	Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A
EAY191-E5	II	ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6
EAY191-N5	II	Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial